Nizar Souayah, MD, FAAN, FAANEM, FANA

Dr. Nizar Souayah is an internationally renowned, triple board-certified neurologist with over 25 years of clinical and academic leadership. As the Founding Director of Premier NeuroHealth, he is a globally recognized authority in neuroimmunology and complex neuromuscular disorders, specifically Myasthenia Gravis (MG), GBS, and CIDP. A pioneer in precision medicine, Dr. Souayah has a pending U.S. international patent application for innovative neuroinflammation diagnostics aimed at enabling earlier intervention and individualized treatment strategies. He also serves as a Key Opinion Leader and strategic consultant for biopharmaceutical companies advancing novel therapeutics in neuromuscular and neuroimmunological disease. Throughout his distinguished career, he has authored over 400 peer-reviewed works and served in key academic roles, including as Professor of Neurology and Neurosciences at Rutgers University and Founding Director of both the Rutgers GBS/CIDP Center of Excellence and the COVID-19 Neurology Center of Excellence. He completed his residency as Chief Resident at Temple University and his fellowship in Neuromuscular Disease at Harvard Medical School/Massachusetts General Hospital. Dr. Souayah is celebrated for his patient-centered philosophy, integrating advanced biomarkers and genetic data with a holistic approach to neurowellness. Whether navigating traditional therapies or evolving biologic treatments, his expertise in MG is sought worldwide for second-opinion consultations. He remains at the forefront of the field, leading Centers of Excellence and providing authoritative tele-neuromuscular care for the most challenging cases. Dr. Souayah can be reached for consultations at premierneurohealth.com/contact/.

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.